Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:04:42 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:AZN - ASTRAZENECA PLC SPON ADR EACH REP 0.50 ORD SHS - https://www.astrazeneca.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AZN - Q0.868.60·69.051.068.79-0.47-0.72,992.1203,94924,26769.59  69.60  68.6787.67  61.2419:14:24Jul 1415 min RT 2¢

Recent Trades - Last 10 of 24267
Time ETExPriceChangeVolume
19:14:24Q68.90-0.365
19:13:45Q68.90-0.365
19:01:06Q68.895-0.3651
18:57:18Q68.90-0.361
18:24:35Q68.89-0.371
18:15:38Q68.90-0.3650
18:14:49Q68.89-0.37100
18:04:15Q68.89-0.371
18:03:26Q68.89-0.372
18:00:15Q68.89-0.371

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-14 07:00U:AZNNews ReleaseBaxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
2025-07-08 08:50U:AZNNews ReleaseGlobal Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
2025-06-24 07:00U:AZNNews ReleaseDATROWAY(TM) approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
2025-06-02 08:00U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
2025-06-01 08:05U:AZNNews ReleaseIMFINZI(TM) (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
2025-06-01 08:00U:AZNNews ReleaseCamizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
2025-05-21 07:00U:AZNNews ReleaseAstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
2025-05-19 12:34U:AZNNews ReleaseStatistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
2025-05-13 07:00U:AZNNews ReleaseAstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
2025-05-09 07:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
2025-05-07 07:00U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
2025-05-02 07:00U:AZNNews ReleaseBREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
2025-04-29 02:00U:AZNNews ReleaseAstraZeneca's Q1 2025 Financial Results
2025-04-21 07:00U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer
2025-03-31 12:00U:AZNNews ReleaseAZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
2025-03-31 07:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
2025-03-25 19:02U:AZNNews ReleaseNew study results reinforce TAGRISSO(TM) (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
2025-03-14 12:00U:AZNNews ReleaseAstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer
2025-03-07 07:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers
2025-03-01 17:30U:AZNNews ReleasePositive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps